哌拉西林钠他唑巴坦钠与阿奇霉素联用治疗肺部感染的研究

目的:观察哌拉西林钠他唑巴坦钠联合阿奇霉素治疗肺部感染的临床疗效和安全性。方法:122例中、重度肺部感染的患者随机分为A、B、C组。A组给予哌拉西林钠他唑巴坦钠4.5g,静脉滴注,bid,3h后给予阿奇霉素0.5g,静脉滴注,qd。B组给予哌拉西林钠他唑巴坦钠4.5g,静脉滴注,bid。C组给予阿奇霉素0.5g,静脉滴注,qd。治疗3d后,B、C组联用其它抗菌药。3组总疗程为7～14d。观察比较3组的疗效和细菌清除率,并记录患者不良反应的发生情况。结果:治疗3d后,A组的有效率及细菌清除率明显高于B、C组,且有显著性差异(P<0.05)。而治疗7～14d后,3组的疗效及不良反应发生率比较,差异无统计学意义(P>0.05)。结论:对于中、重度肺部感染的患者,应用哌拉西林钠他唑巴坦钠联合阿奇霉素治疗快速、安全、有效。

Study on the Combination of Piperacillin Sodium and Tazobactam Sodium with Azithromycin in the Treatment of Pulmonary Infection

OBJECTIVE： To observe the clinical efficacy and safety of piperacillin sodium and tazobactam sodium combined with azithromycin in the treatment of pulmonary infection. METHODS： 122 cases of moderate and severe pulmonary infection were randomly divided into 3 groups： group A, group B and group C. Group A were treated with Piperacillin sodium and tazobactam sodium 4.5 g via i.v. ggt twice a day, 3 hours later, groups A received azithromycin 0.5 g via i.v. gtt once a day. Group B were treated with Piperacillin sodium and tazobactam sodium 4.5 g via i.v. gtt twice a day. Group C were treated with azithromycin 0.5 g via i.v. gtt once a day. After 3 days of treatment, group B and group C were additionally given other antibacterial agents. The treatment course lasted 7 to 14 days. Clinical efficacy and bacterial clearance rates in 3 groups were observed and compared. Adverse reactions of patients were recorded. RESULTS： After 3 days of treatment, the effective rates and bacterial clearance rates of group A were significantly higher than those of group B and group C, there were significant differences（P〈0.05）. Clinical efficacy and the incidence of ADR were no significantly different among 3 groups after 14 days of treatment（P〉0.05）. CONCLUSION： Piperacillin sodium and tazobactam sodium combined with azithromycin is safe and effective in the treatment of moderate and severe pulmonary infection.